The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND
The 2012 United States Preventive Services Task Force recommendation against screening for prostate cancer has impacted rates of prostate‐specific antigen (PSA) screening and appears to be associated with declining prostate cancer incidence. Our objective was to characterize health care utilization that may explain these observed trends.
METHODS
MarketScan claims, which capture >30...
BACKGROUND
Racial disparities in prostate cancer survival (PCS) narrowed during the prostate‐specific antigen (PSA) era, suggesting that screening may induce more equitable outcomes. However, the effects of lead time and overdiagnosis can inflate survival even without real screening benefit.
METHODS
A simulation model of PCS in the early PSA era (1991‐2000) was created. The modeled survival started...
ObjectiveTo validate six previously identified markers among men at increased risk of prostate cancer (African‐American men and those with a family history of prostate cancer) enrolled in the Prostate Cancer Risk Assessment Program (PRAP), a prostate cancer screening study.
Patients and MethodsEligibility criteria for PRAP include age 35–69 years with a family history of prostate cancer, African‐American...
Study Type – Diagnosis (validating cohort)Level of Evidence 1bWhat's known on the subject? and What does the study add?The European Randomized study of Screening for Prostate Cancer (ERSPC) showed a reduction in prostate cancer mortality of 21% for PSA‐based screening at a median follow‐up of 11 years. In the ERSPC, men are screened at 4‐year intervals. A prostate biopsy is recommended for men with...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.